CN106950380B - A kind of gastric cancer monitoring reagent box and its application method - Google Patents
A kind of gastric cancer monitoring reagent box and its application method Download PDFInfo
- Publication number
- CN106950380B CN106950380B CN201710120659.4A CN201710120659A CN106950380B CN 106950380 B CN106950380 B CN 106950380B CN 201710120659 A CN201710120659 A CN 201710120659A CN 106950380 B CN106950380 B CN 106950380B
- Authority
- CN
- China
- Prior art keywords
- gastric cancer
- reagent
- concentration
- diagnosis
- reagent box
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention provides a kind of gastric cancer monitoring reagent box and its application methods, which includes: reagent A: concentration is that the SDS of addition 5% in the ammonium bicarbonate soln of 10mM is formulated；Reagent B: concentration is that no less than 2.4 units/μ L exoglycosidase is added in 10%NP40 to be formulated；Reagent C: the mixed liquor of the DMSO of the 1.2M citric acid and 2M organic matter reducing agent of isometric 20mM APTS；Reagent D: 0.5 μ L concentration is the NH of 100mM, pH 5.64AC, the sialidase of 0.2 μ L, 2.50 μ L hydrogen peroxide.The kit assesses patients with gastric cancer as diagnosis index based on the finger-print of oligonucleotide chain in detection blood glycoprotein, with the neoplasm staging of diagnosis of gastric cancer.
Description
Technical field
The invention belongs to biomedicine technical fields, and in particular to a kind of gastric cancer monitoring reagent box and its application method.
Background technique
Gastric cancer is the health that the pernicious tumor disease of one kind threatens global human, although the hair of gastric cancer in recent decades
Decreasing trend is totally presented in raw rate, but incidence still accounts for second in all cancers, and the death rate holds pride of place.In global range
The incidence of the gastric cancer of male is only second to lung, prostate cancer and colorectal cancer, accounts for the 4th；The gastric cancer incidence of women occupies the 5th
Position, after coming breast cancer, cervical carcinoma, colorectal cancer and lung cancer.It is analyzed from age of onset, there is rejuvenation trend, young man
Incidence gastric cancer rate is gradually increasing.It is distinguished from gender, male patient is more than women, and female patient is in the majority in young patient.I
The characteristics of " three high three is low " is presented in state's patients with gastric cancer status, i.e. disease incidence, the rate of transform, the death rate is high；Early diagnosis rate, radical excision
Rate, 5 years survival rates are low.Found according to the Research statistics of WanqingChen et al., from 2000 to 2011 year during, although stomach
Reduced trend is presented in the incidence and the death rate of cancer, but the gastric cancer incidence of male still accounts for the second of all cancers, extremely
The rate of dying accounts for third position, although the gastric cancer incidence of women only accounts for the 5th of all cancers, the death rate accounts for second.
The pathological of gastric cancer is the different types of gastric cancer based on histology and morphology structure and characteristics of cell biology,
Its morphosis and biological behaviour are different, and epidemiology and molecular mechanism are also different, so that existing gastric cancer pathological
System is numerous.With the continuous development of science and technology, the understanding of gastric cancer is also gradually deepened, studies gastric cancer from initial tissue morphology
To at present from Molecular level study gastric cancer, while the parting of gastric cancer is also with occurring constantly variation, from general form parting to group
It knits parting to be arrived again based on environment, heredity and epidemiological classification, arrives Genotyping.Main at present most commonly Lauren points
Type and WHO parting.
The cancer diagnosis reagent box occurred at present is all some common tumor markers of detection, and sensitivity and accuracy are all
It is relatively low.Reason is mainly that selected tumor marker individual event detection often has significant limitation, it is difficult to meet quick diagnosis
It is required that.
Glycoprotein molecule is made of polypeptide chain and sugared two parts.Any variation in seroglycoid can reflect human body
Physiological change.The occurrence and development changed with various tumours that sugar group research in recent years also shows oligonucleotide chain have close
Correlation (bibliography: Liu, X-E, Desmyter, L, Gao, C-F, Laroy, W, Dewaele, S, Vanhooren, V,
Wang, L, Zhuang, H, Callewaert, N, Libert, C, Contreras, R, Chen, C.N-Glycomic changes
in hepatocellμLar carcinoma patients with liver cirrhosisinduced by hepatitis
B virus.Hepatology, 46,1426-1435,2007.).
In view of the uncertainty of gastric cancer monitoring, there is an urgent need to a kind of reagents and monitoring and evaluation that can effectively monitor gastric cancer at present
Method.
Summary of the invention
The technical issues of solution: present invention aim to address the uncertainties that existing detection method monitors gastric cancer, mention
For a kind of gastric cancer monitoring reagent box and its application method, the carbohydrate of the glucosides key connection by detecting blood glycoprotein
(oligosaccharides) content changes to assess the recurrence of the progress of gastric cancer and rear tumour.
Technical solution: a kind of gastric cancer monitoring reagent box is made of following reagent:
Reagent A: concentration is that the SDS of addition mass concentration 5% in the ammonium bicarbonate soln of 10mM is formulated；
Reagent B: mass concentration is that no less than 2.4 units/μ L exoglycosidase is added in 10% NP40 to be formulated；
Reagent C: the mixed liquor of the DMSO of the 1.2M citric acid and 2M organic matter reducing agent of isometric 20mM APTS；
Reagent D: 0.5 μ L concentration is the NH of 100mM, pH 5.64AC, the no less than sialidase of 0.2 μ L, 2.50 μ L dioxygens
Water.
Wherein, the organic matter reducing agent is NaCNBH3。
Wherein, the volume of reagent A can be 3 μ L, and the volume of reagent B can be 3 μ L, and the volume of reagent C can be 4 μ L,
The volume of reagent D can be 3 μ L.
The application method of above-mentioned gastric cancer monitoring reagent box, comprising the following steps:
Step 1, the reagent A of 3 μ L is added in the 3 μ L serum toward one times of dilution, carries out reaction of degeneration (RD), is added 3 μ L reagent B, and 37
It is DEG C dry after reaction 4 hours, obtain sample；
Step 2,4 μ L reagent Cs are added in gained sample, carries out fluorescent marker, it is anti-that 150 μ L water end marks is then added
It answers, the sample after obtaining fluorescent marker；
Step 3,3 μ L reagent Ds are added to the sample after 5 μ L fluorescent markers, terminal sialic acid is carried out and reacts, 100 μ are added
The water end mark of L is reacted, and the sample of terminal sialic acid reaction is obtained；
Step 4, the sample for taking 8 μ L that terminal sialic acid is gone to react, carries out oligonucleotide chain piece separation with ABI sequenator, obtains figure
Spectrum.
Further, the condition of step 1 reaction of degeneration (RD) is to heat not less than 95 DEG C.
Further, the condition of fluorescent marker is 60-70 DEG C of heating in step 2.
Further, the condition for going terminal sialic acid to react in step 3 is to heat not higher than 45 DEG C.
Above-mentioned gastric cancer monitoring reagent box can be used for the blood or human body fluid that detection includes oligonucleotide chain ingredient.
The utility model has the advantages that gastric cancer monitoring reagent box of the invention is made based on the finger-print of oligonucleotide chain in detection blood glycoprotein
Patients with gastric cancer is assessed for diagnosis index, with the neoplasm staging of diagnosis of gastric cancer.The detection method can allow numerous gastric cancers
Patient receives conventional, Non-invasive detection, helps doctor to detect gastric cancer, and can monitor progression of disease in time.
Detailed description of the invention
Fig. 1 is the flow diagram analyzed in embodiment 1 using the N- oligonucleotide chain fingerprint technique of serum；
Fig. 2 is human serum G-Test map used in Example 1；
Fig. 3 is the serum G-Test map of healthy control group in embodiment 1；
Fig. 4 is the serum G-Test map of patients with lung cancer in embodiment 1.
Specific embodiment
Below by further the present invention will be described in detail.It should be pointed out that following explanation be only to the present invention claims
The technical solution of protection for example, not to any restrictions of these technical solutions.Protection scope of the present invention is with appended
Subject to the content that claims are recorded.
The experimental method of specific experiment condition is not specified in the following example, usually according to normal condition or according to manufactory
Condition proposed by quotient.
The study found that the change of the carbohydrate content of the glucosides key connection of blood glycoprotein and the tissue of patients with gastric cancer
There are significant ground correlations between.Further, assessment gastric cancer clinical monitoring method can effectively screening, periodical evaluation gastric cancer
The recurrence of tumour after progress and treatment.
In the present invention, it is used as diagnosis index to stomach using the oligonucleotide chain fingerprint technique of serum (abbreviation G-Test method)
Cancer patient is assessed.This method has main steps that, discharges the widow of simultaneously fluorescent marker serum or the glycoprotein in plasma sample
Sugar chain；The content of the oligonucleotide chain of fluorescent marker or finger-print (abbreviation G-Test map) in separating and measuring sample；Analysis ratio
Compared with oligosaccharides finger-print, Testing index parameter is obtained, detailed process is shown in Fig. 1.It is normal that this method can allow numerous patients with gastric cancer to receive
Rule, Non-invasive detection help doctor to detect gastric cancer, and can monitor the progress of generation and the morbidity of disease in time.
Specifically, for monitor get a cancer of the stomach or the composition of gastric cancer risk be selected from following oligonucleotide chains: NA3F, NA2F,
NA2FB, NGA2F, NGA2FB and NA3.In following embodiment, using the ratio of (NA3+NA2FB)/NA3F come diagnosis of gastric cancer
Detection.As shown in Fig. 2, the G-Test map of human serum probably shows nearly 10 N- oligonucleotide chains peak, different oligonucleotide chains
Different migrations is shown because of the difference of molecular size, that is, shows that the different peaks on G-Test map then represent
Different oligonucleotide chains；The relative concentration content of oligonucleotide chain then shows measured peak height.
Above-mentioned oligosaccharides abbreviation respectively indicates are as follows: NGA2F, galactolipin missing contain two days of core fucose (α 1,6Fuc)
Line；NGA2FB, galactolipin missing is with the core fucose (α 1,6Fuc) for halving acetylglucosamine (G1cNAc) modification
Two antennas；NG1A2F, the single missing of galactolipin core fucose (α 1,6Fuc) two antennas (single agalacto,
Core- α -1,6-fucosylated biantennary)；NA2, two antennas (bigalacto, biantennary)；
NA2F, core fucose (α 1,6Fuc) two antennas；NA2FB, with bisection acetylglucosamine (GlcNAc) modification
Core fucose (α 1,6Fuc) two antennas；NA3, triantennary；NA3F, branch's fucose (α 1,3/1,2Fuc) modification
Triantennary.
A kind of gastric cancer monitoring reagent box provided by the invention is made of following reagent:
Reagent A (denaturation buffer): the ammonium hydrogen carbonate SDS of 10mM；
Reagent B(exoglycosidase reaction buffer): 2.4 units of exoglycosidase final concentration/μ L is 10%
NP40 ；
Reagent C (APTS marks buffer): the 20mM APTS (being dissolved in 1.2M citric acid) of equal volume is mixed
With 2M organic matter reducing agent (being dissolved in DMSO)；
Reagent D (sialidase reaction solution): 0.5 μ L 100mM NH4AC, pH 5.6；0.2 μ L sialidase, 2.50 μ L
Hydrogen peroxide.
In the present invention, the preferred NaCNBH of organic matter reducing agent3。
Embodiment 1
One, test sample
This experiment has collected the serum of 49 patients with gastric cancer altogether, and serum collection comes from Zhenjiang First Peoples Hospital.Health is right
Zhenjiang First Peoples Hospital is come from according to group 57 serum.
Above 49 patients receive Clinical Laboratory Analyses diagnosis and histological examination and meet standard (a) chosen below
It is patients with gastric cancer；(b) exclude human immunodeficiency virus (human immunodeficiencyvirus, HIV) etc. other
Virus infection；(c) serum collection is not before patient receives any treatment, clinical blood routine, biochemistry, tumor markers,
The data such as DNA carrying capacity and the serum same period collect.Above data is used to assess the degree of the stomach functional lesion of patient.
Two, equipment and reagent
Equipment is mainly ABI sequenator (biologic applications company of the U.S. Applied Biosystems), and therewith
The identical capillary electrophoresis of action principle.Reagent mainly contains reagent A (denaturation buffer): the ammonium hydrogen carbonate 5% of 10mM
SDS ；Reagent B (PNGaseF reaction buffer): 2.4 units of exoglycosidase final concentration/μ L is in 10% NP40；
Reagent C (APTS marks buffer): the 20mM APTS(for mixing equal volume is dissolved in 1.2M citric acid) and 2M
NaCNBH3(being dissolved in DMSO)；Reagent D (sialidase reaction solution): 0.5 μ L100mM NH4AC ；0.2 μ L sialidase, 2.50
μ L hydrogen peroxide.
Three, the operating procedure of the G-Test map in serum sample is detected:
The operation sequence guarantor of G-Test atlas analysis includes four steps:
Step 1, free oligonucleotide chain is prepared with the N- hydrolysis of glycoside bond enzyme of specificity: toward one times of 3 μ L serum of dilution
The reagent A of 3 μ L is added, 95 DEG C are denaturalized for heating 5 minutes；Then the reagent B of (the 3 μ L) of equal volume, 37 DEG C of reactions 4
It is dry after hour；
Step 2, the reagent C of 4 μ L, 65 DEG C of heating 2 the free oligonucleotide chain of fluorescent marker: are added in the liquid of step 1
Hour carries out fluorescent marker, and the water end mark reaction of 150 μ L is then added；
Step 3, it removes terminal sialic acid: taking the liquid of the step 2 of 5 μ L fluorescent markers, the reagent of 3 μ L is then added
D, 45 DEG C of heating carry out terminal sialic acid in 3 hours and react, and the water end mark reaction of 100 μ L is then added；
Step 4, it the N- oligonucleotide chain of separation analysis of fluorescence label: takes and goes terminal sialic acid reaction obtained by 8 μ L steps 3
Liquid carries out the separation of N- oligonucleotide chain piece with ABI3500dx sequenator, obtains G-Test map.
It tests and analyzes:
The each peak in G-Test map obtained to measurement carries out quantum chemical method, is come with the relative amount at each peak
It indicates (%): quantifying calculating divided by the summation of the height at all peaks with the peak value at each peak, G-TEST is calculated
Value.Compare the difference of the relative amount of patients with gastric cancer and healthy control group with statistics, concrete outcome is as shown in the table:
| G-TEST value | NGA2F | NGA2FB | NG1A2F | NG1A2F | NA2 | NA2F | NA2FB | NA3 | NA3F | (NA2FB+NA3)/NA3F |
| Normal group 57 | 6.75 | 0.95 | 5.49 | 5.48 | 48.52 | 15.92 | 4.48 | 9.92 | 2.49 | 5.78 |
| Gastric cancer group 49 | 7.66 | 1.16 | 5.17 | 5.57 | 48.50 | 14.22 | 4.66 | 6.76 | 6.30 | 1.81 |
The G-Test map of human serum represents different N- oligonucleotide chain peaks, shows difference because of the difference of molecular size
Migration, that is, show that the different peaks on G-Test map then represent different oligonucleotide chains；Oligonucleotide chain it is relatively dense
Degree content then shows measured peak height.As shown in Figure 3 and Figure 4, the NA2FB of gastric cancer group and Normal group, with second-class
Divide acetylglucosamine (GlcNAc) core fucose (α 1,6Fuc) two antennas of modification；NA3, triantennary；NA3F, point
The triantennary of branch fucose (α 1,3/1,2Fuc) modification has obvious gap, the carbon of the N- glucosides key connection of blood glycoprotein
There are significant ground correlations between the change of content and the histology of patients with gastric cancer for hydrate (N- oligosaccharides).Research finds benefit
Significant come diagnosis of gastric cancer detection effect with the ratio of (NA3+NA2FB)/NA3F, the threshold value of setting (NA3+NA2FB)/NA3F is greater than
It is normal group when 4, there are 51 to meet the requirements in normal group 57, accuracy 89.5%.Determine the threshold of (NA3+NA2FB)/NA3F
It is gastric cancer group when value is less than 2, gastric cancer group 49 have 43 to meet the requirements, accuracy 87.8%.As a result illustrate blood glycoprotein
The carbohydrate (N- oligosaccharides) of N- glucosides key connection between the change of content and the histology of patients with gastric cancer there are significant
Correlation.
Claims (1)
1. a kind of composition is preparing the application in stomach cancer diagnosis reagent, the composition by NA3F, NA2F, NA2FB, NGA2F,
NGA2FB and NA3 composition, the composition is by the ratio of (NA3+NA2FB)/NA3F come diagnosis of gastric cancer.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710120659.4A CN106950380B (en) | 2017-03-02 | 2017-03-02 | A kind of gastric cancer monitoring reagent box and its application method |
| PCT/CN2018/077714 WO2018157832A1 (en) | 2017-03-02 | 2018-03-01 | Gastric cancer monitoring kit and use method therefor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710120659.4A CN106950380B (en) | 2017-03-02 | 2017-03-02 | A kind of gastric cancer monitoring reagent box and its application method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106950380A CN106950380A (en) | 2017-07-14 |
| CN106950380B true CN106950380B (en) | 2019-01-11 |
Family
ID=59467136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710120659.4A Active CN106950380B (en) | 2017-03-02 | 2017-03-02 | A kind of gastric cancer monitoring reagent box and its application method |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN106950380B (en) |
| WO (1) | WO2018157832A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106950379B (en) * | 2017-03-02 | 2019-01-22 | 江苏先思达生物科技有限公司 | A kind of lung cancer monitoring reagent box and its application method |
| CN106950380B (en) * | 2017-03-02 | 2019-01-11 | 江苏先思达生物科技有限公司 | A kind of gastric cancer monitoring reagent box and its application method |
| CN109100507A (en) * | 2017-06-20 | 2018-12-28 | 江苏先思达生物科技有限公司 | The method for building up of the seroglycoid N- sugar group spectrum model of chronic hepatitis hepatic injury |
| CN114058673A (en) * | 2021-09-15 | 2022-02-18 | 江苏先思达生物科技有限公司 | Fatty liver detection reagent and application thereof in fatty liver detection |
| CN114032282A (en) * | 2021-09-15 | 2022-02-11 | 陈翠英 | Prostate cancer detection reagent and application thereof in prostate cancer detection |
| CN114032284A (en) * | 2021-09-15 | 2022-02-11 | 陈翠英 | Esophageal cancer detection reagent and application thereof in esophageal cancer detection |
| CN114032283A (en) * | 2021-09-15 | 2022-02-11 | 陈翠英 | Intestinal cancer detection reagent and application thereof in intestinal cancer detection |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101451975A (en) * | 2008-12-29 | 2009-06-10 | 浙江大学 | Method for detecting cancer of stomach prognosis and staging blood serum protein |
| CN102565318A (en) * | 2012-01-11 | 2012-07-11 | 陈翠英 | Reagent for liver cancer monitoring, staging and prognosis risk assessment and method thereof |
| WO2016036705A1 (en) * | 2014-09-03 | 2016-03-10 | Musc Foundation For Research Development | Glycan panels as specific tumor tissue biomarkers |
| CN105699473A (en) * | 2016-03-23 | 2016-06-22 | 深圳市老年医学研究所 | Gastric cancer sialoprotein fingerprint spectrum molecular diagnosis module building method |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101779128A (en) * | 2007-06-14 | 2010-07-14 | 弗拉芒区生物技术研究所 | Diagnostic test for the detection of early stage liver cancer |
| CN101576495B (en) * | 2009-06-09 | 2011-11-09 | 中国人民解放军第二军医大学 | Method for detecting N-glycome log (P9/P4) in serum and detecting system and application thereof |
| US20110092374A1 (en) * | 2009-10-16 | 2011-04-21 | Vib, Vzw | Methods for producing substantially homogeneous hybrid or complex n-glycans in methylotrophic yeasts |
| CN102707062A (en) * | 2011-03-27 | 2012-10-03 | 上海交通大学附属第一人民医院 | Method for detecting chronic hepatitis B liver fibrosis serum N-glycome peak mark and application thereof |
| US20150017669A1 (en) * | 2013-07-10 | 2015-01-15 | Hudson Surface Technology, Inc. | Process and its application for improving reproducibility in maldi-tof glycan profiling of human serum: experimental procedure and application to the screening for ovarian tumors |
| CN105372214B (en) * | 2014-08-18 | 2019-06-28 | 中国科学院上海有机化学研究所 | A method of identifying the N- connection oligosaccharide structure of new erythropoiesis stimulating protein |
| CN104807998B (en) * | 2015-05-12 | 2017-01-11 | 先思达（南京）生物科技有限公司 | Diagnostic kit for early liver cancer and use method thereof |
| CN106950380B (en) * | 2017-03-02 | 2019-01-11 | 江苏先思达生物科技有限公司 | A kind of gastric cancer monitoring reagent box and its application method |
-
2017
- 2017-03-02 CN CN201710120659.4A patent/CN106950380B/en active Active
-
2018
- 2018-03-01 WO PCT/CN2018/077714 patent/WO2018157832A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101451975A (en) * | 2008-12-29 | 2009-06-10 | 浙江大学 | Method for detecting cancer of stomach prognosis and staging blood serum protein |
| CN102565318A (en) * | 2012-01-11 | 2012-07-11 | 陈翠英 | Reagent for liver cancer monitoring, staging and prognosis risk assessment and method thereof |
| WO2016036705A1 (en) * | 2014-09-03 | 2016-03-10 | Musc Foundation For Research Development | Glycan panels as specific tumor tissue biomarkers |
| CN105699473A (en) * | 2016-03-23 | 2016-06-22 | 深圳市老年医学研究所 | Gastric cancer sialoprotein fingerprint spectrum molecular diagnosis module building method |
Non-Patent Citations (2)
| Title |
|---|
| 一种利用DSA—FACE分析寡糖链的方法;刘波等;《生物技术通讯》;20081130;第19卷(第6期);885-888 |
| 胃癌患者外周血N-糖特征性改变及其与胃癌证型相关性研究;秦丽萍;《第二军医大学 博士学位论文》;20131030;19-29 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106950380A (en) | 2017-07-14 |
| WO2018157832A1 (en) | 2018-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106950380B (en) | A kind of gastric cancer monitoring reagent box and its application method | |
| CN106950379B (en) | A kind of lung cancer monitoring reagent box and its application method | |
| US20180068058A1 (en) | Methods and compositions for sample identification | |
| CN102565318B (en) | Reagent for liver cancer monitoring, staging and prognosis risk assessment and method thereof | |
| CN105671181B (en) | Gene marker, primer, probe and kit for detecting lung cancer | |
| US10648039B2 (en) | Use of methylation sites in Y chromosome as prostate cancer diagnosis marker | |
| ES2963390T3 (en) | Method to predict the effectiveness of chemotherapy in patients with breast cancer | |
| CN105603101A (en) | Application of system for detecting expression quantity of eight miRNAs in preparation of product for diagnosing or assisting in diagnosing hepatocellular carcinoma | |
| CN102782151A (en) | Circulating miRNA as non-invasive markers for diagnosis and staging in prostate cancer | |
| CN100999758A (en) | Alpha-L-fucosidosidase active tested process and diagnostic reagent of alpha-L-fucosidosidase | |
| EP2371968B1 (en) | Method for judging risk of cancer recurrence, computer program, and computer system | |
| CN108531586A (en) | A kind of relevant cycle miRNA marker and its application on X chromosome of and Computer-aided Diagnosis of Breast Cancer | |
| CN102089443A (en) | Method and apparatus for determining a probability of colorectal cancer in a subject | |
| CN107164508A (en) | Gene marker for detecting liver cancer and application thereof | |
| CN109762898A (en) | A kind of application of tumor markers CA9 and UCA1 in the kit for preparing the probability that Noninvasive testing suffers from bladder cancer | |
| CN109609634A (en) | One kind circulation miRNA marker relevant to carcinoma of endometrium auxiliary diagnosis and its application | |
| CN107641649B (en) | Primer pair, kit and method for detecting stability of NR27 locus of microsatellite | |
| CN109355390A (en) | For detecting kit and its application of colorectal cancer | |
| CN105779465A (en) | CDKN2A gene fragment and application of primers of CDKN2A gene fragment in diagnosing tumors | |
| RU2336822C1 (en) | Method for mammary gland cancer forecasting | |
| CN112534068A (en) | Method for early diagnosis and post-treatment monitoring of breast cancer using fluid biopsy of multiple oncogene biomarkers | |
| CN107723343A (en) | A kind of method of gene quantification analysis | |
| CN111220804B (en) | Marker for evaluating breast cancer chemotherapy effect based on serum glycoprotein | |
| WO1998046993A2 (en) | Method for diagnosing cancer by measuring the presence of creatine kinase inhibitor | |
| CN104865210A (en) | Single liquid reagent for AFU (alpha-fucosidase) determination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170703 Address after: 225312 Jiangsu city of Taizhou province China pharmaceutical Road East, Xinyang City Road on the north side of building six on the eastern side of G26 Applicant after: Jiangsu first star Biological Technology Co., Ltd. Applicant after: Pioneer star (Nanjing) Biological Technology Co., Ltd. Applicant after: Star long (Nanjing) Biological Technology Co., Ltd. Changzhou Ji Tai Biological Technology Co., Ltd. Address before: 210046, Nanjing, Jiangsu province Qixia District Yao street, Gan family side, No. 108 east 4 Applicant before: Pioneer star (Nanjing) Biological Technology Co., Ltd. Applicant before: Jiangsu first star Biological Technology Co., Ltd. Applicant before: Changzhou Ji Tai Biotechnology Co., Ltd. |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200701 Address after: 22F, block a, gene building, No. 211, pubin Road, Pukou District, Nanjing, Jiangsu Province Co-patentee after: JIANGSU XIANSIDA BIOTECHNOLOGY Co.,Ltd. Patentee after: XIANSIDA (NANJING) BIOTECHNOLOGY Co.,Ltd. Address before: 225312 Jiangsu city of Taizhou province China pharmaceutical Road East, Xinyang City Road on the north side of building six on the eastern side of G26 Co-patentee before: XIANSIDA (NANJING) BIOTECHNOLOGY Co.,Ltd. Patentee before: JIANGSU XIANSIDA BIOTECHNOLOGY Co.,Ltd. Co-patentee before: CHANGZHOU JITAI BIOLOGICAL TECHNOLOGY Co.,Ltd. |